Safety Information Of Compound Semaglutide

At Weight Balance, we prioritize providing accurate and clear information about the treatments we offer. Below, you’ll find essential details about Compound Semaglutide, its uses, limitations, and safety information to help you make an informed decision.

What is Compound Semaglutide?

Compound Semaglutide is an injectable medication used to assist with weight management in adults struggling with obesity or excess weight and related health conditions. It works best when combined with a reduced-calorie diet and increased physical activity.

Who Can Use Compound Semaglutide?

It is designed for:

It should not be used by:

How is Compound Semaglutide Taken?

Important Safety Information

Thyroid Cancer Risk

In animal studies, semaglutide caused thyroid tumors. While this hasn’t been confirmed in humans, individuals with a personal or family history of thyroid cancer should avoid its use. Watch for symptoms like lumps in the neck, hoarseness, or trouble swallowing.

Other Serious Risks

Common Side Effects

Limitations of Use

Compound Semaglutide is not FDA-approved and does not undergo the same rigorous evaluations as FDA-approved medications. It should not be used alongside other GLP-1 receptor agonists or weight-loss medications. Its safety in children under 18 or individuals with pancreatitis is not established.

Before Using Compound Semaglutide

Inform your Weight Balance provider about:

If you are using oral contraceptives, switch to a non-oral method to maintain effectiveness or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

How to Learn More

This overview provides essential information about Compound Semaglutide but does not replace the guidance of a Weight Balance provider. For detailed instructions or further questions, consult your Weight Balance provider.

At Weight Balance, your health and safety are our priorities. Let us help you achieve your weight management goals with confidence and care.